Annual balance sheet for Intensity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.54 | 1.31 | 14.8 | 2.59 | 11.9 |
| Net Total Receivables | 0.051 | 0.062 | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.73 | 1.45 | 15.5 | 3.36 | 12.7 |
| Net Property, Plant And Equipment | 0.318 | 0.139 | 0.147 | 0.122 | 0.096 |
| Other Long Term Assets | |||||
| Total Assets | 5.22 | 1.76 | 17.3 | 4.78 | 14.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 3.72 | 6.82 | 3.96 | 1.75 | 2.15 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.9 | 6.85 | 4.13 | 1.86 | 2.23 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.32 | -5.1 | 13.2 | 2.92 | 11.9 |
| Total Liabilities & Shareholders' Equity | 5.22 | 1.76 | 17.3 | 4.78 | 14.1 |
| Total Common Shares Outstanding |